Ligelizumab And Omalizumab Effective For Treating Chronic Spontaneous Urticaria, JAMA findings suggest

The biologic medicines ligelizumab (72 or 240 mg) and omalizumab (300 or 600 mg) can be suggested as effective therapies for chronic spontaneous urticaria (CSU) that is not controlled by H1 antihistamines. The findings were reported in the journal JAMA Dermatology. Chronic spontaneous urticaria (CSU) is a kind of autoimmune condition. Therapy is frequently challenging, although the initial approach necessitates the use of high-dose non-sedating antihistamines. No study has been able to produce a comprehensive evaluation of the advantages and risks of all known therapies for persistent spontaneous urticaria caused by H1 antihistamines.

Surapon Nochaiwong, Chiang Mai University, Chiang Mai, Thailand, and colleagues, therefore, aimed to evaluate different treatment effects of pharmacologic treatments among patients with H1 antihistamine–refractory CSU.

The researchers explored internet databases from conception until April 19, 2021 for this aim. It comprised randomised controlled studies (RCTs) that looked at the benefits and risks of pharmacologic therapies in adolescent or adult CSU patients. who had an insufficient reaction to H1 antihistamines were independently assessed for inclusion by two investigators
There were 23 randomised clinical studies with a total of 2480 individuals that evaluated 18 different treatments or doses with placebo.

The results of the study were:

  • The standardized mean differences for change in urticaria symptoms were −1.05 for ligelizumab, 72 mg;−1.07 for ligelizumab, 240 mg;−0.77 for omalizumab, 300 mg;and −0.59 for omalizumab, 600 mg.
  • No significant differences in treatment unacceptability were observed.With respect to benefits and harms, the network estimates illustrated that the most efficacious treatments were achieved with ligelizumab, 72 or 240 mg (large beneficial effect), and omalizumab, 300 or 600 mg (moderate beneficial effect).

Nochaiwong and the team concluded that “The findings in this meta-analysis suggest that the biologic agents ligelizumab, 72 or 240 mg, and omalizumab, 300 or 600 mg, can be recommended as effective treatments for patients with CSU who have had an inadequate responseto H1 antihistamines. Head-to-head trials with high methodologic quality and harmonized design and outcome definitions are needed to help inform subsequent international guidelines for the management of CSU.”

Medically Speaking Team

Recent Posts

Harness the Power of Rice Water

Rice water, rich in inositol, antioxidants, vitamins, and minerals, protects hair from sunlight damage and…

10 hours ago

“8 Powerful Herbs and Supplements to Beat Bloating and Boost Your Gut Health Naturally”

Natural Remedies for Bloating: 8 Herbs and Supplements That Work Wonders for Your Gut Health…

10 hours ago

“Unlock the Power of Oil Pulling: Discover How This Simple Practice Improves Oral Health and Freshens Your Breath”

Benefits of Oil Pulling: Stops Bad Breath, Keeps Gums Healthy, But Can't Replace Brushing Oil…

10 hours ago

WHY DO YOU EXPERIENCE RUNNY NOSE AFTER EATING SPICY FOOD?

Spicy food – whether it’s a dash of chili in your curry, a spoonful of…

10 hours ago

“4 Simple Tests to Spot Adulterated Wheat Flour: Protect Your Health with These Easy Checks”

How To Identify Adulterated Wheat Flour? Try These 4 Easy Tests Wheat flour is a…

10 hours ago

“Unlock the Power of Jaggery: 10 Surprising Health Benefits of Eating It After Every Meal”

Reasons That Will Make You Eat Jaggery After Every Meal (Potential Health Benefits Inside) Jaggery,…

11 hours ago